Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

[Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].

Lu D, Qin YZ, Li LD, Shi HX, Lai YY, Liu YR.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):370-6. doi: 10.7534/j.issn.1009-2137.2014.02.019. Chinese.

PMID:
24763007
2.

PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes.

Qin YZ, Zhu HH, Liu YR, Wang YZ, Shi HX, Lai YY, Xu LP, Liu DH, Jiang Q, Li LD, Jiang B, Liu KY, Huang XJ.

Leuk Lymphoma. 2013 Jul;54(7):1442-9. doi: 10.3109/10428194.2012.743656. Epub 2012 Nov 26.

PMID:
23110703
3.

Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.

Qin Y, Zhu H, Jiang B, Li J, Lu X, Li L, Ruan G, Liu Y, Chen S, Huang X.

Leuk Res. 2009 Mar;33(3):384-90. doi: 10.1016/j.leukres.2008.08.026. Epub 2008 Oct 23.

PMID:
18950857
4.

Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.

Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, Girotto M, Marinone C, Ferrero D, Gallamini A, Levis A, Saglio G; Piedmont Study Group on Myleodysplastic Syndromes.

J Clin Oncol. 2003 May 15;21(10):1988-95.

PMID:
12743153
5.

[Clinical significance of the Wilms' tumor 1 mRNA expression in childhood myelodysplastic syndrome].

Cheng YF, Zhang LP, Liu YR, Qin YZ, Wu J, Liu GL.

Zhonghua Xue Ye Xue Za Zhi. 2012 Jul;33(7):536-40. Chinese.

PMID:
22967413
6.

Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.

Ueda Y, Mizutani C, Nannya Y, Kurokawa M, Kobayashi S, Takeuchi J, Tamura H, Ogata K, Dan K, Shibayama H, Kanakura Y, Niimi K, Sasaki K, Watanabe M, Emi N, Teramura M, Motoji T, Kida M, Usuki K, Takada S, Sakura T, Ito Y, Ohyashiki K, Ogawa H, Suzuki T, Ozawa K, Imai K, Kasai M, Hata T, Miyazaki Y, Morita Y, Kanamaru A, Matsuda A, Tohyama K, Koga D, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F.

Leuk Lymphoma. 2013 Jul;54(7):1450-8. doi: 10.3109/10428194.2012.745074. Epub 2012 Nov 26.

PMID:
23110324
7.

[PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].

Qin YZ, Li JL, Zhu HH, Li LD, Chang Y, Hao L, Wang YZ, Jiang B, Lu XJ, Liu YR, Huang XJ, Chen SS.

Zhonghua Xue Ye Xue Za Zhi. 2008 Jul;29(7):441-5. Chinese.

PMID:
19035174
8.

The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.

Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K, Soma T, Oka Y, Tatekawa T, Oji Y, Tsuboi A, Kim EH, Kawakami M, Fuchigami K, Tomonaga M, Toyama K, Aozasa K, Kishimoto T, Sugiyama H.

Leukemia. 1999 Mar;13(3):393-9.

PMID:
10086730
9.

Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels.

Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T, Oji Y, Tamaki H, Kyo T, Dohy H, Hiraoka A, Masaoka T, Kishimoto T, Sugiyama H.

Blood. 1996 Sep 15;88(6):2267-78.

10.

WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.

Zhong L, Wei L, Chen J, Huang X, Gong Y, Lu Y.

Mol Diagn Ther. 2015 Aug;19(4):205-12. doi: 10.1007/s40291-015-0147-2.

PMID:
26138637
11.

[Significance of monitoring WT1 mRNA levels of peripheral blood and bone marrow in acute myeloid leukemia].

Kitamura K, Nakano Y, Watamoto K, Koga D, Naoe T.

Rinsho Ketsueki. 2010 Dec;51(12):1748-55. Japanese.

PMID:
21258184
12.

WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?

Bader P, Niemeyer C, Weber G, Coliva T, Rossi V, Kreyenberg H, Gerecke A, Biondi A.

Eur J Haematol. 2004 Jul;73(1):25-8.

PMID:
15182334
13.

[Detection of methylation levels of multi-genes by real-time PCR in patients with myelodysplastic syndrome].

Wang YC, DU X, Geng SX, Li YY, Weng JY, Lu ZS, Zhong LY, Deng CX, Lai PL, Huang X.

Zhonghua Xue Ye Xue Za Zhi. 2011 Apr;32(4):254-8. Chinese.

PMID:
21569709
14.

Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.

Santamaría C, Ramos F, Puig N, Barragán E, de Paz R, Pedro C, Insunza A, Tormo M, Del Cañizo C, Diez-Campelo M, Xicoy B, Salido E, Sánchez del Real J, Hernández M, Chillón C, Sanz GF, García-Sanz R, San Miguel JF, González M.

Ann Hematol. 2012 Dec;91(12):1887-95. doi: 10.1007/s00277-012-1538-7. Epub 2012 Aug 9.

PMID:
22875062
15.

[Significance of quantification of WT1 mRNA for monitoring minimal residual disease in acute myeloid leukemia patients].

Qin YZ, Ruan GR, Li JL, Fu JY, Chang Y, Wang H, Li LD, Liu YR, Chen SS.

Zhonghua Xue Ye Xue Za Zhi. 2005 Nov;26(11):649-52. Chinese.

PMID:
16620548
16.

Wilms' tumor-1 transcript in peripheral blood helps diagnose acute myeloid leukemia and myelodysplastic syndrome in patients with pancytopenia.

Yamauchi T, Matsuda Y, Takai M, Tasaki T, Hosono N, Negoro E, Ikegaya S, Takagi K, Kishi S, Yoshida A, Urasaki Y, Ueda T.

Anticancer Res. 2012 Oct;32(10):4479-83.

PMID:
23060576
17.

[WT1 gene expression in myelodysplastic syndrome and its clinical implication].

Huang J, Jin J, Xu WL.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2006 Mar;35(2):132-5. Chinese.

PMID:
16610077
18.

[Change of cytokine expressions on bone marrow mesenchymal stem cells in patients with bone marrow failure syndromes and its significance].

Yang SM, Lu SF, Fei XM, Zhang JF, Shen WY, Li JY, Lu H.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Dec;18(6):1560-3. Chinese.

PMID:
21176370
20.

Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring.

Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O, Browne P, Stary J, McCann SR, Trka J, Lawler M.

Leukemia. 2006 Feb;20(2):254-63.

PMID:
16341043
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk